Acute renal toxicity associated with suramin in the treatment of prostate cancer

Cancer. 1994 Sep 1;74(5):1612-4. doi: 10.1002/1097-0142(19940901)74:5<1612::aid-cncr2820740519>3.0.co;2-q.

Abstract

The use of suramin, a polysulfonated naphthylurea, in the treatment of advanced prostate cancer currently is being investigated. A 52-year-old man developed acute renal dysfunction after receiving nine doses of suramin. His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10.8 mg/dl during the next 6 days. The patient was not rechallenged with suramin, and his renal function returned to baseline within the next 3 weeks. Future investigators of this drug should be aware of the possibility of such a reaction with parenteral administration.

Publication types

  • Case Reports

MeSH terms

  • Acute Kidney Injury / chemically induced*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma / drug therapy*
  • Carcinoma / radiotherapy
  • Carcinoma / secondary
  • Combined Modality Therapy
  • Creatinine / blood
  • Creatinine / urine
  • Flutamide / administration & dosage
  • Humans
  • Hydrocortisone / administration & dosage
  • Kidney / drug effects*
  • Leuprolide / administration & dosage
  • Male
  • Middle Aged
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / radiotherapy
  • Suramin / administration & dosage
  • Suramin / adverse effects*
  • Suramin / blood
  • Suramin / pharmacokinetics

Substances

  • Suramin
  • Flutamide
  • Creatinine
  • Leuprolide
  • Hydrocortisone